Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Community Pharmacy Services | 5 | 2022 | 22 | 2.630 |
Why?
|
| Pharmaceutical Services | 5 | 2023 | 41 | 1.580 |
Why?
|
| Pharmacists | 9 | 2025 | 74 | 1.450 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2024 | 301 | 1.320 |
Why?
|
| Pharmacy | 4 | 2023 | 35 | 1.140 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2025 | 21 | 1.060 |
Why?
|
| Education, Pharmacy | 6 | 2025 | 117 | 1.030 |
Why?
|
| Pharmacies | 2 | 2022 | 19 | 0.950 |
Why?
|
| Hearing Loss | 1 | 2024 | 39 | 0.840 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2025 | 340 | 0.790 |
Why?
|
| Health Literacy | 3 | 2025 | 34 | 0.740 |
Why?
|
| Diabetes Mellitus | 4 | 2024 | 215 | 0.710 |
Why?
|
| Thyroid Diseases | 1 | 2019 | 9 | 0.640 |
Why?
|
| Colchicine | 1 | 2019 | 16 | 0.640 |
Why?
|
| Influenza, Human | 1 | 2021 | 92 | 0.630 |
Why?
|
| Pericarditis | 1 | 2019 | 14 | 0.630 |
Why?
|
| Referral and Consultation | 2 | 2024 | 98 | 0.630 |
Why?
|
| Cystic Fibrosis | 3 | 2018 | 34 | 0.620 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 78 | 0.610 |
Why?
|
| Aspirin | 1 | 2019 | 125 | 0.590 |
Why?
|
| Schools, Pharmacy | 4 | 2025 | 25 | 0.580 |
Why?
|
| Migraine Disorders | 2 | 2015 | 22 | 0.550 |
Why?
|
| Antimicrobial Stewardship | 1 | 2017 | 5 | 0.540 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 46 | 0.530 |
Why?
|
| Anti-Bacterial Agents | 3 | 2017 | 534 | 0.500 |
Why?
|
| Guideline Adherence | 1 | 2017 | 95 | 0.500 |
Why?
|
| Pneumonia | 1 | 2017 | 89 | 0.500 |
Why?
|
| Humans | 26 | 2025 | 28581 | 0.480 |
Why?
|
| Patient Education as Topic | 3 | 2025 | 91 | 0.460 |
Why?
|
| Program Evaluation | 3 | 2025 | 172 | 0.450 |
Why?
|
| Education, Pharmacy, Continuing | 1 | 2014 | 2 | 0.450 |
Why?
|
| Vaccination | 3 | 2021 | 192 | 0.390 |
Why?
|
| Edema | 1 | 2012 | 18 | 0.370 |
Why?
|
| Students, Pharmacy | 3 | 2025 | 84 | 0.370 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 109 | 0.350 |
Why?
|
| Insulin | 1 | 2012 | 323 | 0.320 |
Why?
|
| Societies, Pharmaceutical | 2 | 2025 | 5 | 0.290 |
Why?
|
| Aged | 4 | 2025 | 5525 | 0.290 |
Why?
|
| Leadership | 2 | 2025 | 54 | 0.270 |
Why?
|
| Obesity | 1 | 2012 | 675 | 0.250 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 988 | 0.240 |
Why?
|
| Fellowships and Scholarships | 1 | 2025 | 40 | 0.240 |
Why?
|
| Female | 12 | 2025 | 15471 | 0.220 |
Why?
|
| Adult | 7 | 2025 | 7922 | 0.210 |
Why?
|
| Diabetes Complications | 1 | 2024 | 66 | 0.210 |
Why?
|
| Blood Glucose | 1 | 2025 | 310 | 0.210 |
Why?
|
| Surveys and Questionnaires | 5 | 2025 | 994 | 0.210 |
Why?
|
| Health Personnel | 1 | 2024 | 96 | 0.200 |
Why?
|
| Male | 10 | 2025 | 13771 | 0.200 |
Why?
|
| Mass Screening | 1 | 2024 | 156 | 0.200 |
Why?
|
| Oklahoma | 2 | 2024 | 1038 | 0.190 |
Why?
|
| Middle Aged | 6 | 2024 | 7310 | 0.190 |
Why?
|
| Outpatients | 1 | 2022 | 44 | 0.190 |
Why?
|
| Data Collection | 2 | 2012 | 105 | 0.190 |
Why?
|
| Immunization Programs | 1 | 2021 | 15 | 0.170 |
Why?
|
| Seasons | 1 | 2021 | 94 | 0.170 |
Why?
|
| Hypothyroidism | 1 | 2019 | 11 | 0.160 |
Why?
|
| Hyperthyroidism | 1 | 2019 | 10 | 0.160 |
Why?
|
| Drug Interactions | 1 | 2019 | 79 | 0.160 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 75 | 0.160 |
Why?
|
| Patient Discharge | 2 | 2021 | 108 | 0.150 |
Why?
|
| Models, Educational | 1 | 2018 | 23 | 0.140 |
Why?
|
| Self Care | 2 | 2015 | 42 | 0.140 |
Why?
|
| United States | 4 | 2025 | 2201 | 0.140 |
Why?
|
| Community-Acquired Infections | 1 | 2017 | 31 | 0.130 |
Why?
|
| Patient Medication Knowledge | 1 | 2017 | 1 | 0.130 |
Why?
|
| Hepatitis B Vaccines | 1 | 2017 | 3 | 0.130 |
Why?
|
| Azithromycin | 1 | 2017 | 11 | 0.130 |
Why?
|
| Caregivers | 1 | 2018 | 118 | 0.130 |
Why?
|
| Retrospective Studies | 3 | 2017 | 2612 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2017 | 100 | 0.120 |
Why?
|
| Glycated Hemoglobin A | 2 | 2014 | 64 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2017 | 458 | 0.120 |
Why?
|
| Medication Reconciliation | 1 | 2015 | 16 | 0.120 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 26 | 0.120 |
Why?
|
| Adolescent | 4 | 2018 | 3165 | 0.110 |
Why?
|
| Self-Assessment | 1 | 2014 | 10 | 0.110 |
Why?
|
| School Health Services | 1 | 2014 | 36 | 0.110 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2014 | 2 | 0.110 |
Why?
|
| Prediabetic State | 1 | 2014 | 10 | 0.110 |
Why?
|
| Triazoles | 1 | 2014 | 16 | 0.110 |
Why?
|
| Pyrazines | 1 | 2014 | 24 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 96 | 0.110 |
Why?
|
| Asthma | 1 | 2014 | 60 | 0.110 |
Why?
|
| Advisory Committees | 2 | 2024 | 33 | 0.100 |
Why?
|
| Educational Measurement | 1 | 2014 | 131 | 0.100 |
Why?
|
| Diet | 1 | 2015 | 232 | 0.100 |
Why?
|
| Patients | 1 | 2012 | 17 | 0.100 |
Why?
|
| Young Adult | 3 | 2017 | 2804 | 0.090 |
Why?
|
| Professional Role | 1 | 2012 | 46 | 0.090 |
Why?
|
| Linear Models | 1 | 2012 | 202 | 0.090 |
Why?
|
| Overweight | 1 | 2012 | 113 | 0.090 |
Why?
|
| Curriculum | 2 | 2023 | 296 | 0.070 |
Why?
|
| Child | 3 | 2021 | 2271 | 0.070 |
Why?
|
| Ambulatory Care Facilities | 2 | 2018 | 54 | 0.070 |
Why?
|
| Focus Groups | 1 | 2024 | 101 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2025 | 893 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 26 | 0.050 |
Why?
|
| Entrepreneurship | 1 | 2018 | 3 | 0.040 |
Why?
|
| Models, Psychological | 1 | 2018 | 81 | 0.030 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 31 | 0.030 |
Why?
|
| Influenza Vaccines | 1 | 2018 | 51 | 0.030 |
Why?
|
| Commerce | 1 | 2018 | 54 | 0.030 |
Why?
|
| Hepatitis B | 1 | 2017 | 13 | 0.030 |
Why?
|
| Solutions | 1 | 2016 | 31 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2017 | 36 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 149 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 426 | 0.030 |
Why?
|
| Motivation | 1 | 2018 | 213 | 0.030 |
Why?
|
| Documentation | 1 | 2015 | 27 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2017 | 394 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 164 | 0.030 |
Why?
|
| Complementary Therapies | 1 | 2015 | 14 | 0.030 |
Why?
|
| Counseling | 1 | 2015 | 57 | 0.030 |
Why?
|
| Caffeine | 1 | 2015 | 39 | 0.030 |
Why?
|
| Central Nervous System Stimulants | 1 | 2015 | 32 | 0.030 |
Why?
|
| Infant | 1 | 2018 | 1019 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 251 | 0.030 |
Why?
|
| Sitagliptin Phosphate | 1 | 2014 | 1 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2017 | 250 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2016 | 1272 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 2045 | 0.020 |
Why?
|
| Rhizobium | 1 | 1990 | 8 | 0.020 |
Why?
|
| Plant Physiological Phenomena | 1 | 1990 | 19 | 0.020 |
Why?
|
| Chromosomes, Bacterial | 1 | 1990 | 20 | 0.020 |
Why?
|
| Genes, Bacterial | 1 | 1990 | 109 | 0.020 |
Why?
|
| Cosmids | 1 | 1990 | 2 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1990 | 23 | 0.010 |
Why?
|
| Plants, Medicinal | 1 | 1990 | 18 | 0.010 |
Why?
|
| DNA Transposable Elements | 1 | 1990 | 34 | 0.010 |
Why?
|
| Fabaceae | 1 | 1990 | 15 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1990 | 208 | 0.010 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 1990 | 158 | 0.000 |
Why?
|
| Mutation | 1 | 1990 | 864 | 0.000 |
Why?
|